Publications

Journal of mass spectrometry : JMS

A simple and sensitive assay for the quantitative analysis of paclitaxel in human and mouse plasma and brain tumor tissue using coupled liquid chromatography and tandem mass spectrometry.

01-12-2004

Rapid communications in mass spectrometry : RCM

Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4-benzenedisulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

02-11-2004

British journal of cancer

A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer.

18-10-2004

Journal of mass spectrometry : JMS

Quantitative analysis of the P-glycoprotein inhibitor Elacridar (GF120918) in human and dog plasma using liquid chromatography with tandem mass spectrometric detection.

01-10-2004

Clinical colorectal cancer

Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration.

01-09-2004

Methods and findings in experimental and clinical pharmacology

Therapeutic drug monitoring of non-anticancer drugs in cancer patients.

01-09-2004

Cancer research

Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.

15-08-2004

Cancer treatment reviews

Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?

01-08-2004

Investigational new drugs

Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice.

01-08-2004

The Lancet. Oncology

Drug interactions in oncology.

01-08-2004

International journal of pharmaceutics

2-Hydroxypropyl-beta-cyclodextrin extracts 2-phenylphenol from silicone tubing.

08-07-2004

Biomedical chromatography : BMC

Switching from an analogous to a stable isotopically labeled internal standard for the LC-MS/MS quantitation of the novel anticancer drug Kahalalide F significantly improves assay performance.

01-07-2004

Biomedical chromatography : BMC

A more sensitive MS detector does not obviously lead to a more sensitive assay: experiences with ES-285.

01-07-2004

Cancer chemotherapy and pharmacology

Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines.

01-07-2004

Rapid communications in mass spectrometry : RCM

Quantitative analysis of D-24851, a novel anticancer agent, in human plasma and urine by liquid chromatography coupled with tandem mass spectrometry.

25-06-2004

British journal of cancer

Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.

14-06-2004

Clinical cancer research : an official journal of the American Association for Cancer Research

A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.

01-06-2004

Clinical cancer research : an official journal of the American Association for Cancer Research

A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.

15-05-2004

European journal of cancer (Oxford, England : 1990)

Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein.

01-05-2004

Clinical cancer research : an official journal of the American Association for Cancer Research

Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer.

01-04-2004

Investigational new drugs

Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol.

01-04-2004

Journal of pharmacokinetics and pharmacodynamics

Integrated Population Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction.

01-04-2004

Journal of mass spectrometry : JMS

Simple and sensitive liquid chromatographic quantitative analysis of the novel marine anticancer drug Yondelis (ET-743, trabectedin) in human plasma using column switching and tandem mass spectrometric detection.

01-04-2004

Journal of mass spectrometry : JMS

Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electrospray tandem mass spectrometry.

01-03-2004

Journal of mass spectrometry : JMS

Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N',N"-triethylenethiophosphoramide (thiotepa) and N,N',N"-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

01-03-2004

Cancer chemotherapy and pharmacology

The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice.

01-02-2004

Clinical pharmacokinetics

Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy.

30-01-2004

Analytical biochemistry

Development and validation of a method to determine the unbound paclitaxel fraction in human plasma.

01-01-2004

Journal of chromatography. A

Development and validation of a liquid chromatography-ultraviolet absorbance detection assay using derivatisation for the novel marine anticancer agent ES-285 x HCl [(2S,3R)-2-amino-3-octadecanol hydrochloride] and its pharmaceutical dosage form.

12-12-2003

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Bioanalysis of zosuquidar trihydrochloride (LY335979) in small volumes of human and murine plasma by ion-pairing reversed-phase high-performance liquid chromatography.

05-12-2003

British journal of cancer

P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo.

03-11-2003

Cancer research

The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.

01-10-2003

Drug development and industrial pharmacy

Pharmaceutical development of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum anticancer agent AP 5280.

01-10-2003

Clinical cancer research : an official journal of the American Association for Cancer Research

Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.

01-09-2003

Anti-cancer drugs

Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.

01-08-2003

PDA journal of pharmaceutical science and technology

Pharmaceutical quality control of the investigational polymer-conjugated platinum anticancer agent AP 5280.

25-07-2003

Laboratory animals

Cannulation of the jugular vein in mice: a method for serial withdrawal of blood samples.

01-07-2003

Clinical cancer research : an official journal of the American Association for Cancer Research

Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein.

01-07-2003

Anti-cancer drugs

In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood.

01-07-2003

Therapeutic drug monitoring

Sorption of thiotepa to polyurethane catheter causes falsely elevated plasma levels.

01-06-2003

The Journal of biological chemistry

Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells.

16-05-2003

Journal of mass spectrometry : JMS

Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometry.

01-05-2003

Investigational new drugs

Pharmacokinetic-pharmacodynamic guided trial design in oncology.

01-05-2003

Anti-cancer drugs

Metabolism of paclitaxel in mice.

01-03-2003

Journal of pharmaceutical and biomedical analysis

Development of a LC method for pharmaceutical quality control of the antimetastatic ruthenium complex NAMI-A.

26-02-2003

Therapeutic drug monitoring

High-performance liquid chromatographic analysis of the anticancer drug irinotecan (CPT-11) and its active metabolite SN-38 in human plasma.

01-02-2003

Annals of oncology : official journal of the European Society for Medical Oncology

Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer.

01-02-2003

The Journal of pharmacology and experimental therapeutics

Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir.

01-02-2003

Biochemical pharmacology

DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin.

15-01-2003

The oncologist

Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview.

20-12-2002

A simple and sensitive assay for the quantitative analysis of paclitaxel in human and mouse plasma and brain tumor tissue using coupled liquid chromatography and tandem mass spectrometry.

Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4-benzenedisulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer.

Quantitative analysis of the P-glycoprotein inhibitor Elacridar (GF120918) in human and dog plasma using liquid chromatography with tandem mass spectrometric detection.

Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration.

Therapeutic drug monitoring of non-anticancer drugs in cancer patients.

Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.

Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?

Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice.

Drug interactions in oncology.

2-Hydroxypropyl-beta-cyclodextrin extracts 2-phenylphenol from silicone tubing.

Switching from an analogous to a stable isotopically labeled internal standard for the LC-MS/MS quantitation of the novel anticancer drug Kahalalide F significantly improves assay performance.

A more sensitive MS detector does not obviously lead to a more sensitive assay: experiences with ES-285.

Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines.

Quantitative analysis of D-24851, a novel anticancer agent, in human plasma and urine by liquid chromatography coupled with tandem mass spectrometry.

Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.

A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.

A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.

Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein.

Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer.

Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol.

Integrated Population Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction.

Simple and sensitive liquid chromatographic quantitative analysis of the novel marine anticancer drug Yondelis (ET-743, trabectedin) in human plasma using column switching and tandem mass spectrometric detection.

Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electrospray tandem mass spectrometry.

Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N',N"-triethylenethiophosphoramide (thiotepa) and N,N',N"-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.

The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice.

Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy.

Development and validation of a method to determine the unbound paclitaxel fraction in human plasma.

Development and validation of a liquid chromatography-ultraviolet absorbance detection assay using derivatisation for the novel marine anticancer agent ES-285 x HCl [(2S,3R)-2-amino-3-octadecanol hydrochloride] and its pharmaceutical dosage form.

Bioanalysis of zosuquidar trihydrochloride (LY335979) in small volumes of human and murine plasma by ion-pairing reversed-phase high-performance liquid chromatography.

P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo.

The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.

Pharmaceutical development of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum anticancer agent AP 5280.

Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.

Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.

Pharmaceutical quality control of the investigational polymer-conjugated platinum anticancer agent AP 5280.

Cannulation of the jugular vein in mice: a method for serial withdrawal of blood samples.

Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein.

In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood.

Sorption of thiotepa to polyurethane catheter causes falsely elevated plasma levels.

Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells.

Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometry.

Pharmacokinetic-pharmacodynamic guided trial design in oncology.

Metabolism of paclitaxel in mice.

Development of a LC method for pharmaceutical quality control of the antimetastatic ruthenium complex NAMI-A.

High-performance liquid chromatographic analysis of the anticancer drug irinotecan (CPT-11) and its active metabolite SN-38 in human plasma.

Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer.

Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir.

DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin.

Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview.

This site uses cookies